Meningococcal Infections Completed Phase 3 Trials for Bordetella pertussis filamentous hemagglutinin antigen (formaldehyde inactivated) (DB10788)

Also known as: Infections, Meningococcal / Meningococcal Infection / Meningococcal disease / Unspecified meningococcal infection / Meningococcal infection, unspecified / Neisseria meningitidis infection NOS

IndicationStatusPhase
DBCOND0032814 (Meningococcal Infections)Completed3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01144663Immunogenicity and Safety of Meningococcal Vaccine GSK 134612 Co-administered With Pneumococcal and DTPa-HBV-IPV/Hib VaccinesPrevention
NCT00508261Co-Administration of Meningococcal Vaccine GSK134612 With Infanrix Hexa™ Versus Individual Administration of Each VaccinePrevention
NCT00614614Immuno,Safety of GSK Vaccine 134612 Given at Age of 12-15 Months 15-18 Months Post-priming With GSK Vaccine 792014Prevention
NCT01755689Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Meningococcal Vaccine With or Without Co-administration of Cervarix and Boostrix in Female Adolescents and Young AdultsPrevention
NCT01767376Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Meningococcal Conjugate Vaccine (GSK134612) When Co-administered With Boostrix® in Subjects Between 11 and 25 Years of AgePrevention
NCT01340898Immunogenicity and Safety Study of GSK Biologicals' Meningococcal Conjugate Vaccine When Co-administered With Routine Vaccines in Healthy Infants and ToddlersPrevention
NCT00289783Safety and Immunogenicity Study of Hib-MenCY-TT Vaccine Compared to Licensed Hib Conjugate VaccinePrevention